These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 32569514)

  • 21. A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma.
    van Malenstein H; Maleux G; Vandecaveye V; Heye S; Laleman W; van Pelt J; Vaninbroukx J; Nevens F; Verslype C
    Onkologie; 2011; 34(7):368-76. PubMed ID: 21734423
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States.
    Reyes DK; Vossen JA; Kamel IR; Azad NS; Wahlin TA; Torbenson MS; Choti MA; Geschwind JF
    Cancer J; 2009; 15(6):526-32. PubMed ID: 20010173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug-eluting bead transarterial chemoembolization with medium-sized versus small-sized CalliSpheres microspheres in unresectable primary liver cancer.
    Zhang J; Feng GA; Li Y; Wang W
    Asia Pac J Clin Oncol; 2022 Aug; 18(4):388-393. PubMed ID: 34708554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Balloon-Occluded Transcatheter Arterial Chemoembolization (b-TACE) for Hepatocellular Carcinoma Performed with Polyethylene-Glycol Epirubicin-Loaded Drug-Eluting Embolics: Safety and Preliminary Results.
    Lucatelli P; Ginnani Corradini L; De Rubeis G; Rocco B; Basilico F; Cannavale A; Nardis PG; Corona M; Saba L; Catalano C; Bezzi M
    Cardiovasc Intervent Radiol; 2019 Jun; 42(6):853-862. PubMed ID: 30843093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival, tumour response and safety of 70-150 μm versus 100-300 μm doxorubicin drug-eluting beads in transarterial chemoembolisation for hepatocellular carcinoma.
    Huo YR; Xiang H; Chan MV; Chan C
    J Med Imaging Radiat Oncol; 2019 Dec; 63(6):802-811. PubMed ID: 31709778
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Chemoembolization Outcomes Using 70-150 µm and 100-300 µm Drug-Eluting Beads in Treating Small Hepatocellular Carcinoma: A Korean Multicenter Study.
    Lee BC; Kim GM; Park J; Chung JW; Choi JW; Chun HJ; Oh JS; Hyun DH; Yang JH
    Korean J Radiol; 2024 Aug; 25(8):715-725. PubMed ID: 39109500
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancement patterns of hepatocellular carcinoma after transarterial chemoembolization using drug-eluting beads on arterial phase CT images: a pilot retrospective study.
    Chung WS; Lee KH; Park MS; Lee YJ; Kwon J; Baek SE; Kim MJ
    AJR Am J Roentgenol; 2012 Aug; 199(2):349-59. PubMed ID: 22826396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of efficacy and safety by CalliSpheres versus HepaSpheres for drug-eluting bead transarterial chemoembolization in unresectable large hepatocellular carcinoma patients.
    Zhao G; Liu S; Chen S; Ren Z; Li C; Bian J; Wu J; Zhou J; Zhang Y
    Drug Deliv; 2021 Dec; 28(1):1356-1362. PubMed ID: 34180755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion.
    Maeda N; Osuga K; Higashihara H; Tomoda K; Mikami K; Nakazawa T; Nakamura H; Tomiyama N
    Cardiovasc Intervent Radiol; 2012 Feb; 35(1):82-9. PubMed ID: 21203761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of drug-eluting microspheres chemoembolization under cone beam computed tomography control in patients with early and intermediate stage hepatocellular carcinoma.
    Korsic S; Levasic N; Dezman R; Zupan LAL; Trotovsek B; Jansa R; Smid A; Popovic P
    Radiol Oncol; 2022 Aug; 56(3):311-318. PubMed ID: 35535426
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of vascular endothelial growth factor in both conventional and drug eluting beads transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma in HCV patients.
    Farid K; Elalfy H; Abo El-Khair SM; Elgamal H; Besheer T; Elmokadem A; Shabana W; Abed S; Elegezy M; El-Khalek AA; El-Morsy A; Negm A; Elsamanoudy AZ; El Deek B; Amer T; El-Bendary M
    Expert Rev Gastroenterol Hepatol; 2020 Dec; 14(12):1203-1214. PubMed ID: 32933325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transarterial Radioembolization versus Transarterial Chemoembolization Plus Percutaneous Ablation for Unresectable, Solitary Hepatocellular Carcinoma of ≥3 cm: A Propensity Score-Matched Study.
    Yu Q; Thapa N; Karani K; Navuluri R; Ahmed O; Van Ha T
    J Vasc Interv Radiol; 2022 Dec; 33(12):1570-1577.e1. PubMed ID: 36100064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of drug-eluting bead-transcatheter arterial chemoembolization using 100-300 μm versus 300-500 μm CalliSpheres microspheres in patients with advanced-stage hepatocellular carcinoma.
    Yang T; Qin W; Sun X; Wang Y; Wu J; Li Z; Ji F; Zhang L; Liu W
    J Cancer Res Ther; 2020; 16(7):1582-1587. PubMed ID: 33565503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma.
    Facciorusso A; Mariani L; Sposito C; Spreafico C; Bongini M; Morosi C; Cascella T; Marchianò A; Camerini T; Bhoori S; Brunero F; Barone M; Mazzaferro V
    J Gastroenterol Hepatol; 2016 Mar; 31(3):645-53. PubMed ID: 26331807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Balloon-occluded transarterial chemoembolization versus conventional transarterial chemoembolization for the treatment of single hepatocellular carcinoma: a propensity score matching analysis.
    Chu HH; Gwon DI; Kim GH; Kim JH; Ko GY; Shin JH; Ko HK; Yoon HK
    Eur Radiol; 2023 Apr; 33(4):2655-2664. PubMed ID: 36472699
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transarterial Infusion of Epirubicin and Cisplatin Combined With Systemic Infusion of 5-Flurouracil Versus Sorafenib for Hepatocellular Carcinoma With Refractoriness of Transarterial Chemoembolization Using Doxorubicin.
    Yoo SH; Kwon JH; Nam SW; Lee JY; Kim YW; Shim DJ; Lee SW; Jang JW
    Cancer Control; 2020; 27(2):1073274820935843. PubMed ID: 32583687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transarterial Chemoembolization Using 100-μm Drug-Eluting Microspheres in Patients with Hepatocellular Carcinoma: A Prospective Study and Midterm Follow-up.
    Ou HY; Wu YN; Yu CY; Chen CL; Hsu HW; Weng CC; Leung-Chit Tsang L; Huang TL; Tong YS; Lim WX; Cheng YF
    J Vasc Interv Radiol; 2020 Nov; 31(11):1784-1791. PubMed ID: 33023805
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Drug Eluting Bead TACE with Microspheres <150 μm for the Treatment of Hepatocellular Carcinoma.
    Sattler T; Bredt C; Surwald S; Rust C; Rieger J; Jakobs T
    Anticancer Res; 2018 Feb; 38(2):1025-1032. PubMed ID: 29374736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
    Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
    J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive imaging for tumor response to drug-eluting microsphere transarterial chemoembolization in patients with BCLC-C advanced hepatocellular carcinoma.
    Chang KH; Hwang ZA; Chang PY; Lin HH; Shih YL; Chang WC; Huang GS; Hsu HH
    Sci Rep; 2019 Dec; 9(1):20032. PubMed ID: 31882969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.